

List of Tables

Table No.	Title	Page No.
Table 2.1	Current pharmacotherapy for Alzheimer's Disease	39
Table 3.1	Calibration data for Galantamine hydrobromide in Distilled water by UV spectroscopy	58
Table 3.2	Parameters for estimation of Galantamine hydrobromide in distilled water by UV Spectroscopy	59
Table 3.3	Absorbance of Galantamine hydrobromide in presence of Bovine Serum Albumin	60
Table 3.4	Calibration data for Galantamine hydrobromide in plasma by HPLC	63
Table 3.5	Parameters for estimation of Galantamine hydrobromide in plasma by HPLC	64
Table 3.6	Calibration data for Galantamine hydrobromide in Cerebrospinal fluid by HPLC	65
Table 3.7	Parameters for estimation of Galantamine hydrobromide in Cerebrospinal fluid by HPLC	66
Table 3.8	Precision and Accuracy for the separation of modified antibody	71
Table 3.9	Precision and Accuracy for the separation of modified antibody	74
Table 4.1	Quality Target Product Profile and Critical Quality Attributes for Galantamine hydrobromide Nanoparticles	84
Table 4.2	Factors and their respective levels for Plackett Burman design	86
Table 4.3	Design Matrix for Plackett-Burman Design	86
Table 4.4	Fixed Process and Formulation Parameters for Box-Behnken Design	87
Table 4.5	The factors and their levels for Box- Behnken Design	88
Table 4.6	Experimental matrix for Box-Behnken Design	88
Table 4.7	Effect of desolvating agent on particle size.	96
Table 4.8	Effect of rate of addition of desolvating agent on particle size	97
Table 4.9	Effect of rate of addition of desolvating agent on particle size	98
Table 4.10	Results of responses after Plackett –Burman Design	102
Table 4.11	Statistical analysis of effect of variables on responses for Plackett-Burman Design	103
Table 4.12	Results of responses for Box-Behnken Design	105
Table 4.13	Statistical analysis of effect of variables on responses for Box-Behnken Design	107
Table 4.14	<i>In vitro</i> drug release data for plain drug solution and Galantamine hydrobromide loaded nanoparticles by using dialysis technique	115
Table 4.15	<i>Ex vivo</i> drug diffusion studies for plain drug solution and Galantamine hydrobromide loaded nanoparticles	116
Table 4.16	Optimization of cryoprotectant for Galantamine hydrobromide loaded nanoparticles	117
Table 5.1	Thiol concentration in modified antibody after thiolation	133
Table 5.2	Optimization of cryoprotectant for Bapineuzumab loaded nanoparticles	139
Table 6.1	<i>In vitro</i> cytotoxicity of Galantamine hydrobromide loaded nanoparticles at 24 and 48 h	149

Table No.	Title	Page No.
Table 6.2	<i>In vitro</i> cytotoxicity of Bapineuzumab loaded nanoparticles at 24 and 48 h	150
Table 7.1	Concentration of Galantamine hydrobromide in plasma after intra venous drug solution and intranasal nanoparticle administration	159
Table 7.2	Pharmacokinetic parameters with respect to plasma for Galantamine hydrobromide after intra venous drug solution and intranasal nanoparticle administration.	160
Table 7.3	Concentration of Galantamine hydrobromide in Cerebrospinal fluid after intra venous drug solution and intranasal nanoparticle administration	161
Table 7.4	Pharmacokinetic parameters for cerebrospinal fluid of Galantamine hydrobromide after intra venous drug solution and intranasal nanoparticle administration.	162
Table 7.5	Concentration of amyloid after intranasal administration of antibody nanoparticles.	167
Table 7.6	Concentration of amyloid after intravenous administration of antibody solution.	167

List of Figures

Figure No.	Title	Page No.
Figure 2.1	The relationship between ciliary motion and mucus layer composition that allows mucociliary clearance	27
Figure 2.2	Diagram of the olfactory area showing the olfactory epithelium, bulb and tract	27
Figure 2.3	Metabolic pathway leading to amyloid β -peptide formation in AD patients.	36
Figure 3.1	UV Spectrum for Galantamine hydrobromide (120 $\mu\text{g}/\text{mL}$) in distilled water	58
Figure 3.2	Standard plot for Galantamine hydrobromide in distilled water	59
Figure 3.3	UV spectrum of Galantamine hydrobromide in presence of Bovine Serum Albumin	60
Figure 3.4	Representative chromatogram of Galantamine in plasma at 6 $\mu\text{g}/\text{mL}$ standard concentration	63
Figure 3.5	Standard plot for Galantamine hydrobromide in plasma	64
Figure 3.6	Representative chromatogram of Galantamine hydrobromide in Cerebrospinal fluid at 6 $\mu\text{g}/\text{mL}$ standard concentration	65
Figure 3.7	Standard plot for Galantamine hydrobromide in Cerebrospinal fluid	66
Figure 3.8	Elution of antibody through Sephadex G25 resin	68
Figure 3.9	Elution of antibody through Sephadex G100 resin	69
Figure 3.10	Elution of antibody through Sephacryl 200 HR resin	69
Figure 3.11	Elution of antibody through MabSelect resin	74
Figure 4.1	Ishikawa diagram to understand the Critical Quality Attributes contributing to particle size	99
Figure 4.2	Ishikawa diagram for understanding the Critical Quality Attributes contributing to entrapment efficiency	100
Figure 4.3	Risk Priority Number associated with various attributes contributing to formulation of GAL nanoparticles	101
Figure 4.4	Response surface plot and contour plot for the significant variables on particle size	109
Figure 4.5	Response surface plot and contour plot for the significant variables on entrapment efficiency	109
Figure 4.6	Design space for GAL nanoparticles through overlay contour plots	110
Figure 4.7	DSC of (a) BSA (b) Pure Galantamine hydrobromide (c) Physical mixture of Galantamine hydrobromide and BSA (d) Galantamine hydrobromide nanoparticles	111
Figure 4.8	XRD of (a) BSA (b) Pure Galantamine hydrobromide (c) Galantamine hydrobromide nanoparticles	112
Figure 4.9	TEM of Formulation Code BB14	113
Figure 4.10	Three-dimensional AFM topography of Galantamine hydrobromide nanoparticles	114
Figure 4.11	<i>In vitro</i> drug release profile for drug solution and nanoparticle suspension	115
Figure 4.12	<i>Ex vivo</i> drug release profile for drug solution and nanoparticle suspension.	116

Figure No.	Title	Page No.
Figure 5.1	Elution of antibody after thiolation with 50 – fold molar excess for 2 hour	130
Figure 5.2	Elution of antibody after thiolation with 50 – fold molar excess of 2-imminothiolane for 5 hour	131
Figure 5.3	Elution of antibody after thiolation with 100 – fold molar excess of 2-imminothiolane for 2 hour	132
Figure 5.4	Elution of antibody after thiolation with 100– fold molar excess 2-imminothiolane for 5 hour	132
Figure 5.5	Thiol quantification of modified antibody	134
Figure 5.6	Reaction scheme involving thiol and maleimide for formation of covalent bond	135
Figure 5.7	TEM images of (A) blank BSA and (B) Bapineuzumab – BSA nanoparticles respectively	136
Figure 5.8	Detailed three-dimensional AFM topography of Blank (BSA) and Bapineuzumab-BSA	136
Figure 5.9	SDS – PAGE gel image for Actively loaded Bapineuzumab nanoparticles	137
Figure 5.10	Absorbance corresponding to activity of Bapineuzumab in standard solution and in nanoparticles	138
Figure 6.1	Muco ciliary lining after exposure to Galantamine loaded nanoparticles	142
Figure 6.2	Muco ciliary lining after exposure to Bapineuzumab loaded nanoparticles	143
Figure 6.3	Control (exposed only to saline)	143
Figure 6.4	Cytotoxicity studies of Galantamine hydrobromide nanoparticles at 24 and 48 h respectively	150
Figure 6.5	Cytotoxicity studies of Bapineuzumab nanoparticles at 24 and 48 h respectively.	151
Figure 6.6	Cellular uptake using flow cytometry for Galantamine hydrobromide nanoparticles	152
Figure 6.7	Cellular uptake using flow cytometry for Bapineuzumab nanoparticles	153
Figure 6.8	Scatter plot for cellular uptake at 24 hr for Galantamine hydrobromide nanoparticles	153
Figure 6.9	Scatter plot for cellular uptake at 24 hr for Bapineuzumab nanoparticles	154
Figure 7.1	Plasma concentration versus time profile for Galantamine hydrobromide after intra venous drug solution and intranasal nanoparticle administration	160
Figure 7.2	Cerebrospinal fluid concentration versus time profile for Galantamine hydrobromide after intra venous drug solution and intranasal nanoparticle administration	162
Figure 7.3	Standard calibration curve for amyloid concentration	166
Figure 7.4	Relative reduction in amyloid concentration after intranasal administration of nanoparticles	167
Figure 7.5	Relative reduction in amyloid concentration after intravenous administration of antibody solution	168